In It for the Long Haul: Long-Term Benefit With Adjuvant Endocrine Therapy for Premenopausal Women With Early-Stage Steroid Receptor-Positive Breast Cancer.
作者信息
Davidson Nancy E
机构信息
Fred Hutchinson Cancer Center and University of Washington, Seattle, WA.
出版信息
J Clin Oncol. 2022 Dec 10;40(35):4037-4039. doi: 10.1200/JCO.22.01465. Epub 2022 Aug 26.
Abstract
摘要
相似文献
1
In It for the Long Haul: Long-Term Benefit With Adjuvant Endocrine Therapy for Premenopausal Women With Early-Stage Steroid Receptor-Positive Breast Cancer.长期坚持：早期激素受体阳性乳腺癌绝经前女性辅助内分泌治疗的长期获益
J Clin Oncol. 2022 Dec 10;40(35):4037-4039. doi: 10.1200/JCO.22.01465. Epub 2022 Aug 26.
2
Adjuvant hormonal therapy for premenopausal women with breast cancer.绝经前乳腺癌女性的辅助激素治疗。
Semin Oncol. 2006 Dec;33(6):657-63. doi: 10.1053/j.seminoncol.2006.08.014.
3
Endocrine Therapy in Premenopausal Hormone Receptor-Positive Breast Cancer.绝经前激素受体阳性乳腺癌的内分泌治疗
J Oncol Pract. 2016 Nov;12(11):1148-1156. doi: 10.1200/JOP.2016.016865.
4
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.21 基因检测在淋巴结阳性乳腺癌中预测化疗获益。
N Engl J Med. 2021 Dec 16;385(25):2336-2347. doi: 10.1056/NEJMoa2108873. Epub 2021 Dec 1.
5
Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry.绝经前与绝经后激素受体阳性乳腺癌患者的辅助内分泌治疗：基于癌症登记处的大型人群队列研究结果
J Cancer Res Clin Oncol. 2015 Dec;141(12):2229-40. doi: 10.1007/s00432-015-2025-z. Epub 2015 Aug 8.
6
Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases.联合卵巢去势与芳香化酶抑制作为绝经前激素受体阳性转移性乳腺癌的一线治疗：三例报告
Anticancer Drugs. 2006 Sep;17(8):999-1002. doi: 10.1097/01.cad.0000224456.28898.37.
7
Adjuvant endocrine therapy of premenopausal women with early breast cancer: an overview.绝经前早期乳腺癌患者的辅助内分泌治疗：综述
Wien Med Wochenschr. 2010 Apr;160(7-8):167-73. doi: 10.1007/s10354-010-0771-8.
8
Adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive early breast cancer: Evidence evaluation and GRADE recommendations by the Italian Association of Medical Oncology (AIOM).绝经前激素受体阳性早期乳腺癌患者的辅助内分泌治疗：意大利肿瘤医学学会（AIOM）的证据评估和 GRADE 推荐。
Eur J Cancer. 2018 Aug;99:9-19. doi: 10.1016/j.ejca.2018.04.006. Epub 2018 Jun 7.
9
Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.绝经前激素受体阳性乳腺癌的最佳全身治疗。
Breast. 2013 Aug;22 Suppl 2:S165-70. doi: 10.1016/j.breast.2013.07.032.
10
Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer.辅助！在卵巢功能抑制加他莫昔芬治疗雌激素受体阳性乳腺癌的绝经前妇女中添加化疗的有效性的在线评估。
Breast Cancer Res Treat. 2010 Aug;123(1):303-10. doi: 10.1007/s10549-010-0794-2. Epub 2010 Feb 27.
本文引用的文献
1
Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial.一项对照随机临床试验中，辅助戈舍瑞林和他莫昔芬对绝经前乳腺癌患者的 20 年获益。
J Clin Oncol. 2022 Dec 10;40(35):4071-4082. doi: 10.1200/JCO.21.02844. Epub 2022 Jul 21.
2
Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials.芳香酶抑制剂与他莫昔芬在接受卵巢抑制的雌激素受体阳性早期乳腺癌绝经前妇女中的比较：来自四项随机试验的 7030 名女性的患者水平荟萃分析。
Lancet Oncol. 2022 Mar;23(3):382-392. doi: 10.1016/S1470-2045(21)00758-0. Epub 2022 Feb 3.
3
Road Map to Safe and Well-Designed De-escalation Trials of Systemic Adjuvant Therapy for Solid Tumors.安全且精心设计的肿瘤系统辅助治疗降阶梯试验的路线图。
J Clin Oncol. 2020 Dec 1;38(34):4120-4129. doi: 10.1200/JCO.20.01382. Epub 2020 Oct 14.
4
Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update.乳腺癌中雌激素和孕激素受体检测：ASCO/CAP 指南更新。
J Clin Oncol. 2020 Apr 20;38(12):1346-1366. doi: 10.1200/JCO.19.02309. Epub 2020 Jan 13.
5
Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update.激素受体阳性乳腺癌妇女的辅助内分泌治疗：ASCO 临床实践指南更新焦点。
J Clin Oncol. 2019 Feb 10;37(5):423-438. doi: 10.1200/JCO.18.01160. Epub 2018 Nov 19.
6
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.内分泌治疗5年后停药的乳腺癌20年复发风险
N Engl J Med. 2017 Nov 9;377(19):1836-1846. doi: 10.1056/NEJMoa1701830.
7
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.雌激素受体阳性乳腺癌诊断后继续辅助他莫昔芬治疗 10 年与 5 年后停药的长期疗效：ATLAS，一项随机试验。
Lancet. 2013 Mar 9;381(9869):805-16. doi: 10.1016/S0140-6736(12)61963-1.
8
Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials.促黄体生成素释放激素激动剂在激素受体阳性绝经前乳腺癌患者中作为辅助治疗的应用：来自随机辅助试验的个体患者数据的荟萃分析
Lancet. 2007 May 19;369(9574):1711-23. doi: 10.1016/S0140-6736(07)60778-8.
9
Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188).绝经前腋窝淋巴结阳性、类固醇激素受体阳性乳腺癌患者的化疗联合内分泌治疗：INT 0101（E5188）研究结果
J Clin Oncol. 2005 Sep 1;23(25):5973-82. doi: 10.1200/JCO.2005.05.551. Epub 2005 Aug 8.
Zotero 插件